UTIBRON NEOHALER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UTIBRON NEOHALER (UTIBRON NEOHALER).
Long-acting muscarinic antagonist (LAMA); inhibits acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation.
| Metabolism | Primarily hepatic via cytochrome P450 enzymes (CYP2D6 and CYP3A4); also metabolized via ester hydrolysis and direct glucuronidation. |
| Excretion | Primarily fecal (58% of radiolabeled dose) and renal (22%) after intravenous administration, with unchanged drug as minor component. Biliary excretion accounts for fecal elimination. |
| Half-life | Terminal elimination half-life: 22 hours (range 16–33 h) in patients with COPD; supports once-daily dosing. |
| Protein binding | 94–95% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vdss: 179 L (approximately 2.6 L/kg assuming 70 kg); indicates extensive tissue distribution. |
| Bioavailability | Inhalation: absolute bioavailability ~25% (lung delivery); oral bioavailability <1% (due to first-pass metabolism and low absorption). |
| Onset of Action | Inhalation: 5 minutes (FEV1 improvement); peak effect at 1–2 hours. |
| Duration of Action | 24 hours (bronchodilation maintained over 24 h with once-daily dosing). |
1 inhalation (27.5 mcg glycopyrrolate/12.5 mcg formoterol fumarate) twice daily via oral inhalation.
| Dosage form | POWDER |
| Renal impairment | No dosage adjustment recommended for GFR 30 mL/min or greater; avoid use in severe renal impairment (GFR <30 mL/min) due to lack of data. |
| Liver impairment | No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B); not studied in severe impairment (Child-Pugh C), use with caution. |
| Pediatric use | Not approved for pediatric patients; safety and efficacy not established in children. |
| Geriatric use | No specific dosage adjustment required; monitor for anticholinergic and beta2-adrenergic adverse effects in elderly due to possible increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for UTIBRON NEOHALER (UTIBRON NEOHALER).
| Breastfeeding | No data on excretion in human milk. Both glycopyrrolate and indacaterol are likely excreted in milk based on animal studies. M/P ratio unknown. Caution should be exercised when administered to nursing women. |
| Teratogenic Risk | Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, glycopyrrolate and indacaterol (components of Utibron Neohaler) showed no teratogenic effects at exposures up to 50 times the maximum recommended human inhalation dose (MRHDID). However, beta-2 agonists may cause fetal harm (e.g., premature labor, low birth weight). Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to glycopyrrolate or any component of the formulation"]
| Precautions | ["Paradoxical bronchospasm","Worsening of narrow-angle glaucoma","Urinary retention","Immediate hypersensitivity reactions"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal respiratory status, heart rate, blood pressure, and serum potassium (beta-agonist may cause hypokalemia). Fetal monitoring for heart rate and growth if used long-term or in preterm labor risk. |
| Fertility Effects | No human studies. In animal studies, no impairment of fertility was observed with glycopyrrolate or indacaterol at doses up to 50 times MRHDID. |